- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05468229
Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Impaired and Normal Glucose Tolerance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective
To investigate the acute effects of a single dose dorzagliatin on first phase insulin secretion and beta cell glucose sensitivity (βCGS) in individuals with impaired and normal glucose tolerance
Methodology and rationale:
A total of 20 subjects will be recruited, 10 in impaired glucose tolerant (IGT) and 10 in normal glucose tolerant (NGT) groups, respectively. Eligible participants will have a two-hour hyperglycemic clamp following a single dose of dorzagliatin or placebo in a randomized crossover fashion on V2 or V3. Subjects will be randomized to dorzagliatin 50mg or placebo in the IGT and NGT groups. Arterialized blood glucose (venous blood drawn from back of the hand placed in a temperature regulated box), measured every 5 minutes at the bedside Yellow Spring Instrument (YSI) or EKF glucose analyser, will be maintained at 12 mmol/l using an infusion of dextrose. Blood will be sampled for insulin and C-peptide at regular intervals for evaluation of first and second phase insulin secretion. Glucagon-like peptide-1 (GLP-1) and glucagon will be evaluated at regular intervals during the clamp studies. After 14 ± 2 days washout out (Day 14), participants will receive a single dose of dorzagliatin or matched placebo followed by a repeat hyperglycemic clamp to evaluate differences in beta-cell function.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals aged ≥ 18 years but < 65years
- Male or female
- Body mass index of over 18 kg/m2 and < 30 kg/m2
Additional inclusion criteria for IGT group
- Fasting plasma glucose <7.0 mmol/L and HbA1c < 6.5%
- 2 hour plasma glucose ≥7.8 and <11.1 mmol/L on 75g oral glucose tolerance test (OGTT)
- Never been treated with glucose lowering drugs (including traditional Chinese medicine for glycemic control)
Additional inclusion criteria for NGT group
- Fasting plasma glucose <5.6 mmol/L and HbA1c < 5.7%
- 2 hour plasma glucose <7.8 mmol/L on 75g oral glucose tolerance test (OGTT)
- Never been treated with glucose lowering drugs (including traditional Chinese medicine for glycemic control
Exclusion Criteria:
- Subjects who do not agree to participate in this study.
- Country of birth is unknown.
- Body weight less than 45kg.
- Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of recruitment).
- Subjects with severe renal dysfunction as defined by eGFR <30 ml/min/1.73m2 or patients receiving renal dialysis (such as haemodialysis or continuous ambulatory peritoneal dialysis).
- Severe hepatic dysfunction as defined by AST and/or ALT > 3 times upper limit of normal.
- Severe cardiovascular disease, history of stroke, heart failure (NYHA III or IV) or history of myocardial infarction within last 12 months.
- History of drug abuse or excessive alcohol intake based on investigator judgment.
- History of diabetes mellitus.
- Dehydration, diarrhoea or vomiting at the time of recruitment.
- Subjects with severe infection, in perioperative period or with serious injury at the time of recruitment.
- Subjects with anaemia (Haemoglobin <11.0mg/dL or haematocrit <0.35 ) at screening, known iron deficiency, haemoglobinopathies or anaemia due to chronic disease.
- Pregnant or lactating or intending to become pregnant within 30 days after last dose of study drug.
- Participation in a clinical trial with investigational product within 30 days before enrolment.
- Donation or loss of blood (excluding the volume of blood that will be drawn during screening procedures) as follows: ≥300 mL of blood within 30 days prior to study drug administration.
- Subjects judged unsuitable for the study based on investigator judgment.
- Use of strong or moderate CYP3A4 inhibitors or inducers and cannot be discontinued.
- Unwilling or unable to follow protocol requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
matching placebo
|
Matching placebo
|
Active Comparator: dorzagliatin
Dorzagliatin 50 mg single dose
|
single oral dose of dorzagliatin 50 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-hour hyperglycemic clamp
Time Frame: 2-hour
|
first phase insulin secretion
|
2-hour
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021.516-T
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Intolerance
-
Yonsei UniversityNot yet recruitingType 2 Diabetes | Impaired Glucose Intolerance
-
University of California, IrvineUniversity of California, Davis; University of California, San FranciscoCompletedStress, Psychological | Pregnancy Related | Glucose Intolerance During PregnancyUnited States
-
Arizona State UniversityRecruiting
-
University of SaskatchewanRoyal University Hospital FoundationCompletedGlucose IntoleranceCanada
-
Glycemic Index Laboratories, IncDSM Nutritional Products, Inc.Completed
-
Materia Medica HoldingCompletedImpaired Glucose ToleranceRussian Federation
-
Joslin Diabetes CenterCompleted
-
TakedaCompletedImpaired Glucose ToleranceJapan
-
China Academy of Chinese Medical SciencesUnknownImpaired Glucose Tolerance
-
University of TromsoCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States